The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
41
Administered IV
Invicro
New Haven, Connecticut, United States
COMPLETEDBoston Medical Center
Boston, Massachusetts, United States
NOT_YET_RECRUITINGMassachusetts General Hospital (MGH)
Charlestown, Massachusetts, United States
Number of Incidence of Adverse Events (AEs)
Evaluation of AEs regardless of causality, will be reported in the Reported AEs module
Time frame: Baseline Through Day 3
Number of Radiation Absorbed Dose Estimates in Body Organs to Obtain Whole-body Effective Dose
Determination of the radiation dosimetry absorbed dose in body organs and whole-body effective dose
Time frame: Baseline Through Day 3
Number of Uptake of [18F]LY4214835 in Tumor Foci and Other Organs
Evaluation of the uptake of \[18F\]LY4214835 in tumor foci and other organs
Time frame: Baseline Through Day 3
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
CONTACT
Physicians interested in becoming principal investigators please contact
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
BAMF Health Inc.
Grand Rapids, Michigan, United States
NOT_YET_RECRUITINGMemorial Sloan Kettering Cancer Center
New York, New York, United States
RECRUITINGIchor Research
Syracuse, New York, United States
RECRUITING